USPTO serial 97593425
DIVERSITY BY DESIGN
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- KHOURI, SANI PHILIPPE
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with DIVERSITY BY DESIGN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Michael A. Geller
Michael A. Geller DLA PIPER LLP (US)P.O. BOX 64807CHICAGO, IL 60664-0807United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Strategic business consulting, marketing and advertising, public relations communications strategy, information and data collection for business purposes, and business data analytics, namely, analyzing business data to understand and evaluate business performance, all of the aforementioned in the pharmaceutical, biotechnology and life sciences fields; sales promotion services; market analysis and research services; personnel recruitment and placement; recruitment services, namely, advertising clinical trials, recruiting patients, and placing patients for participation in clinical trials for testing of pharmaceuticals and devices; consulting in sales techniques and sales programs; sales volume tracking for others, all in the pharmaceutical, biotechnology and life sciences fields; business consulting in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, pharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval; assisting pharmaceutical and biotechnology companies with applications for new drugs with governmental regulatory bodies; promoting the exchange of health information to promote patient adherence | ACTIVE | — |
| 041 | Education in the field of pharmaceutical sales, namely, providing webinars, providing live workshops, providing on-line non-downloadable videos, providing on-line non-downloadable publications in the nature of articles and white papers, and providing podcasts; training services in the field of pharmaceutical sales; providing on-line non-downloadable newsletters and bulletins in the pharmaceutical, biotechnology and life sciences fields; educational services in the field of clinical trials, namely, providing on-line non-downloadable videos, webinars, live workshops, providing online non-downloadable publications in the nature of articles and white papers, and providing podcasts | ACTIVE | — |
| 042 | Medical, scientific and data analysis research services for others, namely, conducting and analyzing clinical trials in the pharmaceutical, biotechnology and life sciences fields; pharmaceutical drug development services, namely, developing clinical trial methodologies; consulting services in the area of pharmaceutical clinical testing; extended clinical research services for others, namely, computerized data management of clinical trials, biostatistical analysis, environmental consultancy, preclinical research and development evaluation, repairing flawed clinical trials and dossiers, strategic clinical research portfolio management, and biosurveillance monitoring; providing life science and scientific research information to physicians and other health care professionals, patients, and medical, pharmaceutical and biotechnology companies; providing regulatory compliant technical writing services in the field of medical research and clinical studies; consulting services in the field of contract clinical research and contract product development | ACTIVE | — |
| 044 | Providing medical information to physicians, other health care professionals and for medical patients; providing health information regarding the medications and health care products of others, namely, product discontinuations, new formulations, bottle changes, and seasonal information through e-mail alerts and push notifications | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Syneos Health, LLC
- Other trademarks owned by Syneos Health, LLC
- Other trademarks in Class 035
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named DIVERSITY BY DESIGN
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 31, 2025 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Mar 31, 2025 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Dec 10, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 10, 2024 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Dec 9, 2024 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Sep 13, 2024 | TPEX | SOU EXTENSION RECEIVED WITH TEAS PETITION | — |
| Sep 13, 2024 | NREV | NOTICE OF REVIVAL - E-MAILED | — |
| Sep 13, 2024 | PETG | PETITION TO REVIVE-GRANTED | — |
| Sep 13, 2024 | PROA | TEAS PETITION TO REVIVE RECEIVED | — |
| Aug 28, 2024 | EXT3 | SOU EXTENSION 3 FILED | — |
| Feb 29, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 28, 2024 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Feb 28, 2024 | EXT2 | SOU EXTENSION 2 FILED | — |
| Feb 28, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 24, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 22, 2023 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Aug 22, 2023 | EXT1 | SOU EXTENSION 1 FILED | — |
| Aug 22, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 28, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 3, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 3, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 14, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 1, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 1, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 30, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 19, 2022 | NWAP | NEW APPLICATION ENTERED | — |